Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)
NCT04211649 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220
Last updated 2024-07-18
Summary
Leptospirosis is a globally distributed neglected tropical disease affecting subtropical and tropical areas, such as the Caribbean and the Indian Ocean, with favorable climatic conditions for disease transmission. It shows a strong seasonality, with epidemic potential especially after heavy rainfall. A recent systematic review by Costa et al. (2015) places leptospirosis among the leading zoonotic causes of morbidity and mortality worldwide, with 1.03 million cases and 58,900 deaths each year.
Leptospirosis is an important public health problem, particularly within economically vulnerable populations. It is also emerging as a health threat in new settings due to globalization and climate change. Disasters and extreme weather events are recognized to precipitate epidemics.
Clinical manifestations are highly polymorphic, ranging from an anicteric, influenza-like form to severe forms with hepato-renal or pulmonary failures which are associated with high mortality.
Antibiotic therapy should be prescribed early, as soon as leptospirosis is suspected and preferably within the first 5 days, before leptospira spread to the tissues. In the treatment of mild forms, usual antibiotics are oral amoxicillin or doxycycline for a standard treatment duration of 7 days. In hospitalized cases of leptospirosis, parenteral antibiotic therapy with ceftriaxone is often favored as first-line therapy.
The most widely used antibiotics in the French Caribbean and Indian Ocean regions are amoxicillin, doxycyclin and third generation cephalosporins such as ceftriaxone.
Research hypothesis:
The effects of shorter antibiotic therapy periods for other infectious diseases have been explored by several authors. The efficacy of short ceftriaxone treatment has been highlighted for typhoid fever or meningococcal meningitis. In a retrospective series of 21 cases, the interest of short treatment periods (3-6 days) for mild and severe leptospirosis has also been described. A minimal 3-day therapy period would seem necessary in order to biologically confirm leptospirosis diagnosis and to rule out other community-acquired infections.
Our study proposal is the conduct of a non-inferiority trial comparing a shortened antibiotic therapy period of 3 days with the standard treatment period of 7 days in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte).
Originality and innovative aspects:
To our knowledge, the efficacy of a 3-day antibiotic therapy for mild leptospirosis, as compared to the standard 7 day period, has not yet been explored.
In addition, the LEPTO3 study will be among the first clinical trials to focus on the endemic public health problem, which is leptospirosis, at a large geographical level (Caribbean and Indian Ocean regions) and to involve a high level of collaboration between medical and scientific teams of these territories.
Conditions
- Mild Leptospirosis
Interventions
- DRUG
-
3 days of antibiotherapy
Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
Sponsors & Collaborators
-
University Hospital of Guadeloupe
collaborator UNKNOWN -
Centre Hospitalier de Cayenne
collaborator OTHER -
Centre Hospitalier Universitaire de la Réunion
collaborator OTHER -
Hôpital de Mayotte
collaborator UNKNOWN -
University Hospital Center of Martinique
lead OTHER
Principal Investigators
-
André CABIE, Professor · University Hospital of Martinique
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-01
- Primary Completion
- 2027-10-01
- Completion
- 2028-02-01
Countries
- French Guiana
- Guadeloupe
- Martinique
- Mayotte
- Reunion
Study Locations
More Related Trials
-
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
NCT00340691 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis
NCT02919605 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.
NCT02859350 ·Status: COMPLETED ·Phase: PHASE1
-
Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites
NCT01660854 ·Status: COMPLETED ·Phase: NA
-
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
NCT02281669 ·Status: UNKNOWN
-
Sero-epidemiology of Priority Arboviruses in French Guiana
NCT03210363 ·Status: COMPLETED ·Phase: NA
-
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
NCT03303898 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa
NCT02431143 ·Status: COMPLETED ·Phase: PHASE2
-
Pan-Malaria Transmission-Blocking Vaccine AnAPN1
NCT05905432 ·Status: COMPLETED ·Phase: PHASE1
-
Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
NCT01218893 ·Status: COMPLETED ·Phase: NA
-
Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh
NCT03311607 ·Status: COMPLETED ·Phase: PHASE4
-
Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination
NCT01586169 ·Status: COMPLETED ·Phase: NA
-
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
NCT01422954 ·Status: COMPLETED ·Phase: NA
-
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
NCT07235020 ·Status: COMPLETED ·Phase: PHASE2
-
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
NCT02530697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
NCT01032187 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).
NCT06997159 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)
NCT06356974 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)
NCT06293339 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Miltefosine and GM-CSF in Cutaneous Leishmaniasis
NCT03023111 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
NCT00600548 ·Status: COMPLETED ·Phase: PHASE2
-
Epidemiology of Cutaneous Leishmaniasis in Niger, Mali, Togo : Mapping of Clinical Cases, Species, Reservoirs and Vectors of the Disease
NCT06692985 ·Status: COMPLETED
-
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
NCT06040489 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
NCT03534245 ·Status: COMPLETED
-
Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years
NCT00703066 ·Status: UNKNOWN ·Phase: PHASE1